Biohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica
View original at globenewswire.comBiohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica Chicago, Feb…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
In Q3 2024, 115 patent applications were filed specifically for personal health data technologies
80% confidenceFor applications, the monitoring segment generated over 30.25% of the revenue share in 2025
80% confidenceOncology applications accounted for 35 out of 100 revenue dollars in the peptide sector in 2025
80% confidenceIn 2025, parenteral (injectable) formulations made up 80 out of 100 peptide products
80% confidenceWhoop users logged 5.7 trillion steps and 227 billion minutes of sleep by the end of 2025
80% confidenceIn terms of product, the wearables category captured the largest market share at 22.75% in 2025
80% confidence30 out of 100 organizations planned to increase their wellness spending in 2024
80% confidenceVendors shipped 4.3 million smart rings globally in 2024
80% confidence85 out of 100 large workplaces offered comprehensive wellness programs
80% confidenceNorth America led the market with the highest revenue share of 40.5% in 2025
80% confidenceDexcom projected USD 4.66 billion for fiscal year 2025
80% confidenceBy September 2025, trial participants had logged 2,000 cumulative days and 15,000 hours of active BCI engagement
80% confidenceIn 2025, researchers initiated 50 new clinical trials targeting Alzheimer's
80% confidenceSamsung and LG held over 15,000 US patents in 2024
80% confidenceIn 2024, 9 out of 10 corporate wellness programs incorporated digital tracking elements
80% confidenceAbbott's FreeStyle Libre user base swelled to 7 million globally by early 2025
80% confidenceIntellia Therapeutics enrolled 765 participants in its ongoing Phase 3 MAGNITUDE trial in 2025
80% confidenceIn 2024, 31 out of 100 financing deals were Later Stage VC rounds
80% confidenceThe FDA cleared 253 AI-enabled medical devices in 2024 alone, bringing the total number of authorized AI devices to 1,247 by mid-2025
80% confidenceNeuralink enrolled 21 participants in its PRIME clinical trial by January 2026
80% confidenceLevels had served more than 60,000 members and amassed hundreds of millions of glucose data points
80% confidenceHome and personal use settings accounted for over 6 in 10 CGM units deployed in 2024
80% confidenceThe United States hosted 57 out of 100 longevity companies and captured 84 out of 100 deals in 2024
80% confidenceLongevity discovery platforms alone attracted USD 2.65 billion in 2024
80% confidence96 out of 100 of AI devices were authorized via the 510(k) pathway
80% confidenceInvestors closed 325 deals in the longevity biotech sector in 2024, with the first quarter alone attracting USD 3.74 billion in funding
80% confidenceOura was on track to reach 1 billion in sales in 2025
80% confidenceCRISPR Therapeutics had established 50 active treatment centers for Casgevy by the end of 2024, with 50 patients initiating the treatment process globally
80% confidenceUsers with HbA1c levels above 6.5 saw significant reductions after adhering to InsideTracker recommendations based on 5-year retrospective data from 20,000 users
80% confidence48 Phase 1 trials for neuro-cognitive drugs began in 2025, nearly doubling the count from the previous year
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · total ai devices authorized | 1247 count |
| U.S. Food and Drug Administration · ai devices cleared 2024 | 253 count |